Shandong Sinobioway Biomedicine Co., Ltd. (SHE:002581)
China
· Delayed Price · Currency is CNY 6.75
-0.36 (-5.06%)
Apr 30, 2026, 3:04 PM CST
SHE:002581 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 274.81 | 355.66 | 425.78 | 356.18 | 397.44 | Upgrade
|
| Other Revenue | - | 4.75 | 4.01 | 0.9 | 5.27 | Upgrade
|
| Revenue | 274.81 | 360.41 | 429.79 | 357.08 | 402.71 | Upgrade
|
| Revenue Growth (YoY) | -23.75% | -16.14% | 20.36% | -11.33% | 45.47% | Upgrade
|
| Cost of Revenue | 129.6 | 87.67 | 93.29 | 76.64 | 85.83 | Upgrade
|
| Gross Profit | 145.21 | 272.74 | 336.5 | 280.44 | 316.88 | Upgrade
|
| Selling, General & Admin | 269.38 | 336.65 | 453.3 | 426.21 | 477.76 | Upgrade
|
| Research & Development | 18.87 | 25.37 | 59.8 | 27.29 | 38.44 | Upgrade
|
| Other Operating Expenses | -0.82 | 6.31 | 6.78 | 6.24 | 6.83 | Upgrade
|
| Operating Expenses | 287.43 | 363.6 | 492.32 | 456.02 | 520.83 | Upgrade
|
| Operating Income | -142.22 | -90.86 | -155.81 | -175.57 | -203.95 | Upgrade
|
| Interest Expense | - | -0.2 | -9.06 | -9.41 | -6.88 | Upgrade
|
| Interest & Investment Income | - | 67.28 | 174.46 | 3.02 | 3.75 | Upgrade
|
| Earnings From Equity Investments | 16.82 | - | - | 217.45 | 471.94 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0 | - | 0 | -0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | -10.27 | 0.3 | -9.88 | 0.22 | -6.68 | Upgrade
|
| EBT Excluding Unusual Items | -135.66 | -23.49 | -0.29 | 35.72 | 258.18 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -18.65 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 3.77 | 1.16 | -6.33 | 0.05 | -0.15 | Upgrade
|
| Asset Writedown | -43.65 | -69.64 | -293.88 | -13.61 | -0.48 | Upgrade
|
| Legal Settlements | - | -33.27 | - | -15.49 | - | Upgrade
|
| Other Unusual Items | - | -2.29 | -12.76 | 6.05 | 21.05 | Upgrade
|
| Pretax Income | -175.53 | -146.18 | -313.25 | 12.72 | 278.6 | Upgrade
|
| Income Tax Expense | -14.7 | -3.34 | 8.89 | 13.58 | -0.09 | Upgrade
|
| Earnings From Continuing Operations | -160.83 | -142.84 | -322.14 | -0.86 | 278.69 | Upgrade
|
| Minority Interest in Earnings | 44.55 | 5.52 | -10.32 | -13.82 | -7.69 | Upgrade
|
| Net Income | -116.28 | -137.31 | -332.46 | -14.68 | 271 | Upgrade
|
| Net Income to Common | -116.28 | -137.31 | -332.46 | -14.68 | 271 | Upgrade
|
| Shares Outstanding (Basic) | 660 | 660 | 660 | 658 | 660 | Upgrade
|
| Shares Outstanding (Diluted) | 661 | 660 | 660 | 658 | 660 | Upgrade
|
| Shares Change (YoY) | 0.19% | 0.01% | 0.22% | -0.21% | -0.00% | Upgrade
|
| EPS (Basic) | -0.18 | -0.21 | -0.50 | -0.02 | 0.41 | Upgrade
|
| EPS (Diluted) | -0.18 | -0.21 | -0.50 | -0.02 | 0.41 | Upgrade
|
| Free Cash Flow | -433.43 | -15.56 | -40.82 | -85.95 | -106.86 | Upgrade
|
| Free Cash Flow Per Share | -0.66 | -0.02 | -0.06 | -0.13 | -0.16 | Upgrade
|
| Gross Margin | 52.84% | 75.67% | 78.30% | 78.54% | 78.69% | Upgrade
|
| Operating Margin | -51.75% | -25.21% | -36.25% | -49.17% | -50.64% | Upgrade
|
| Profit Margin | -42.31% | -38.10% | -77.35% | -4.11% | 67.29% | Upgrade
|
| Free Cash Flow Margin | -157.72% | -4.32% | -9.50% | -24.07% | -26.53% | Upgrade
|
| EBITDA | -104.62 | -49.7 | -87.43 | -110.63 | -144.38 | Upgrade
|
| EBITDA Margin | -38.07% | -13.79% | -20.34% | -30.98% | -35.85% | Upgrade
|
| D&A For EBITDA | 37.59 | 41.16 | 68.39 | 64.95 | 59.57 | Upgrade
|
| EBIT | -142.22 | -90.86 | -155.81 | -175.57 | -203.95 | Upgrade
|
| EBIT Margin | -51.75% | -25.21% | -36.25% | -49.17% | -50.64% | Upgrade
|
| Effective Tax Rate | - | - | - | 106.75% | - | Upgrade
|
| Revenue as Reported | - | 360.41 | 429.79 | 357.08 | 402.71 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.